WallStSmart

Insmed Inc (INSM)vsTiziana Life Sciences Ltd (TLSA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates -16969% more annual revenue ($606.42M vs $-3.60M). TLSA leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

TLSA

Avoid

16

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

TLSA0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

TLSA4 concerns · Avg: 3.8/10
Price/BookValuation
16.9x4/10

Trading at 16.9x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$167.97M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : TLSA

TLSA has a balanced fundamental profile.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : TLSA

The primary concerns for TLSA are Price/Book, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while TLSA is a value play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

TLSA generates stronger free cash flow (-7M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 16/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Tiziana Life Sciences Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the UK.

Want to dig deeper into these stocks?